I appreciate your post an awful lot. When you take us on a

New Post Public Reply Private Reply Replies (1) Message Board
docj rjs9787 #33422
539
I appreciate your post an awful lot. When you take us on a trip down memory lane, I get reminded of something from the distant pass. I am sure tc, homerbedloe and others would agree your history lessons are on point. Newer members probably can't appreciate the intricacies of what came before Joe's rise to the Generex throne.

When I had the idea for the FoFaN Facebook group, to be honest I saw this decline coming although I did not expect it to get this bad. I had the gut feeling Joe had started losing perspective. How he treated several long term investors, two especially, gave me pause to think as objectively as I could about how he was coping. During my 30 years of patient care, I developed a pretty good sense of reading people. It was clear something had changed. Certainly the official company silence played a role. As did the unusual social media posts. Once the FoGaN group became organized, we decided to reach out to Generex via the letter. I cannot thank tc and Builit enough for their contributions to writing the letter, those who agreed to the content and especially, those who signed. Everyone has been complimentary of the letter's content, stating it is fair, professional and not really threatening in nature. A few would have liked it to be more agressive. The letter was sent to the management teams and BOD's of both GNBT and NGIO. We included the general email boxes and Todd Falls. No response was provided by anyone. It wasn't until I reached out again at the deadline Todd Falls contacted me. Not Joe, the CEO. Todd's message was the same as everyone else(to my knowledge) has gotten.
Phrases like: we have plenty to talk about, we are being prevented from discussing, everyone on the team is still onboard, making progress in everything we have discussed were used over and over. He even said, news could come at anytime, maybe even tomorrow. So... I had some optimism and the FoGaN decided to wait and see if anything happened, expecting something relatively soon. Clearly we were wrong. Here we are many weeks later with silence and 2 filings that are more than fasionably late. Delinquent in fact.

Perhaps, this would be a good time for those who have been on the fence to join the FoGaN group. Yes, I know it is a pain to join FB. Yes, you have to disclose your name, alias as well as prove your share count to be a member. This keeps down the likelihood of having YMB types showing up. Why join? Together we have a stronger voice than we have individually. What is the FoGaN going to do next? That is yet to be decided which means you can have a voice in how we move forward. Is legal action a possibility? I hate that thought having seen the destruction caused by the 13d group in Cytodyn's case. Having said that we are at less than 7 cents. Not much further it can go. NUGX is at .0005. What shares we have(yes, I know they were "free" and also shouldn't be trading...) are worthless.

I wonder what the folks at Altucell and Regentys are thinking.

Even if you don't join do as rjs asks. Reach out to the team members and directors at GNBT and NGIO. Consider this a... if you don't vote you don't get a say...situation.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 2

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 5

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 3

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 4

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 4

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 4

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading

Top 5 Most Recently Viewed Articles

FMC Corporation Transitions by Selling Global Specialty Solutions

Updated Category News Views 137

FMC Corporation Transitions by Selling Global Specialty Solutions FMC Corporation (NYSE: FMC), a prominent player in the agricultural sciences sector, has recently completed the sale of its Global Specialty Solutions business. This significant transaction marks a decisive shift in the company's focus to enhance its core operations and streamline its offerings in the...

Continue Reading
CG Oncology's Promising Future: Analysts Highlight Key Developments

Updated Category News Views 88

Analyst Coverage Boosts CG Oncology's Market Prospects Recently, CG Oncology (NASDAQ:CGON) garnered attention when UBS initiated coverage, assigning a Buy rating with an ambitious price target of $60.00. This endorsement underscores the potential of the company’s flagship program, cretostimogene (creto), which targets non-muscle invasive bladder cancer (NMIBC). Positive...

Continue Reading
Current Trends in Cryptocurrency Market: Key Insights

Updated Category News Views 386

Bearish Pressures on Major Cryptocurrencies In recent days, cryptocurrencies have faced significant bearish trends, with only XRP showing some resilience. This decline raises important questions for traders and investors navigating the volatile crypto landscape. Market Overview: Key Cryptocurrency Prices Here are the current prices and performance metrics for the leading...

Continue Reading
Enhanced Cancer Guidelines Include Key Insights on LEMS

Updated Category News Views 146

Updated Guidelines for LEMS and SCLC In a significant advancement, the National Comprehensive Cancer Network (NCCN) has included essential recommendations for Lambert Eaton Myasthenic Syndrome (LEMS) in their Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC). Importance of VGCC Antibody Testing The updated guidelines emphasize the crucial role of VGCC...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 102

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading